TSH-Lowering Effect of Metformin in Type 2 Diabetic Patients: Differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients by Cappelli, Carlo et al.
TSH-Lowering Effect of Metformin in
Type 2 Diabetic Patients
Differences between euthyroid, untreated hypothyroid, and euthyroid on
L-T4 therapy patients
CARLO CAPPELLI, MD
1
MARIO ROTONDI, MD
2
ILENIA PIROLA, MD
1
BARBARA AGOSTI, MD
3
ELENA GANDOSSI, MD
1
UMBERTO VALENTINI, MD
3
ELVIRA DE MARTINO, MD
1
ANTONIO CIMINO, MD
3
LUCA CHIOVATO, MD
2
ENRICO AGABITI-ROSEI, MD
1
MAURIZIO CASTELLANO, MD
1
OBJECTIVE — Toassesstheinterplaybetweenmetformintreatmentandthyroidfunctionin
type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — The acute and long-term effects of met-
formin on thyroid axis hormones were assessed in diabetic patients with primary hypothyroid-
ismwhowereeitheruntreatedortreatedwithlevothyroxine(L-T4),aswellasindiabeticpatients
with normal thyroid function.
RESULTS — No acute changes were found in 11 patients with treated hypothyroidism.
After 1 year of metformin administration, a signiﬁcant thyrotropin (TSH) decrease (P 
0.001) was observed in diabetic subjects with hypothyroidism who were either treated (n 
29; from 2.37  1.17 to 1.41  1.21 mIU/l) or untreated (n  18; 4.5  0.37 vs. 2.93 
1.48)withL-T4,butnotin54euthyroidsubjects.NosigniﬁcantchangeinfreeT4(FT4)was
observed in any group.
CONCLUSIONS — Metformin administration inﬂuences TSH without change of FT4 in
patients with type 2 diabetes and concomitant hypothyroidism. The need for reevaluation of
thyroid function in these patients within 6–12 months after starting metformin is indicated.
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M
etformin is a widely used drug for
the treatment of type 2 diabetes
(1,2). It is commonly regarded as a
safe drug in that no clinically relevant phar-
macologicinteractionshavebeendescribed
whenitisprescribedtogetherwiththemost
commonly used drugs, with the exceptions
of folate and B12 vitamin (3–5).
Recently it has been reported that met-
formin is able to interfere with thyroid hor-
mone proﬁle, as shown by a decrease in the
serum levels of thyrotropin (TSH) to sub-
normallevelsinhypothyroidpatientsinsta-
ble levothyroxine (L-T4) treatment (6,7).
However,nodataareavailableforuntreated
hypothyroid patients or for euthyroid dia-
betic patients.
Given that both metformin treatment
and hypothyroidism are frequent occur-
rences in diabetic patients (8), we aimed to
further characterize the interplay between
metformin and circulating thyroid function
parameters by evaluating thyroid hormone
axes in different categories of patients who
werestartedonmetforminbecauseofaﬁrst
diagnosis of diabetes.
RESEARCH DESIGN AND
METHODS— A pilot study was con-
ducted with 11 diabetic hypothyroid
patients who were on stable L-T4 substi-
tution(averagedose89.811.5g/day)
to examine the short- to mid-term (up to
24 weeks) effects of metformin adminis-
tration.SerumTSH,freeT4(FT4),freeT3
(FT3), total T4 (TT4), and total T3 (TT3)
were measured at baseline and 6, 24, and
72 h after starting metformin treatment,
aswellasafter3and6monthsoftherapy.
A second study was performed in a
larger cohort of diabetic patients including
29 euthyroid patients on L-T4 substitution
(group I), 18 subclinical hypothyroid pa-
tients who did not receive L-T4 treatment
(group II), and 54 euthyroid patients in
whomthyroiddisordershadbeenexcluded
by a complete thyroid workup based on
clinical history, physical examination, mea-
surement of serum FT4, FT3, TSH, Tg-Ab,
and TPO-Ab, as well as thyroid ultrasonog-
raphy (group III). Type 2 diabetes was di-
agnosed in accordance with American
Diabetes Association criteria (9).
All subjects gave their informed con-
senttothestudy,whichwasperformedin
accordance with the Declaration of
Helsinki.
Statistical analysis
Between- and within-group comparisons
were performed by an ANOVA general
linear model, including repeated-
measuresanalysis(SPSSversion13;SPSS,
Evanston, IL). A P value 0.05 was con-
sidered statistically signiﬁcant.
RESULTS
Pilot study
There were no changes of FT4, FT3, TT4,
and TT3 observed throughout the study.
Overall, a modest reduction of baseline
TSH values (from 2.11  0.55 to 1.5 
0.36 mIU/l, NS) was observed after 6
months of metformin treatment; how-
ever, one patient showed TSH reduction
from 0.5 to 0.09 mIU/l and stable values
of FT4 (from 13.3 to 12.9 pg/ml), FT3
(from 3.12 to 2.92 pg/ml), TT4 (from
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to 1.04 ng/ml). Withdrawal of metformin
in this patient led to an increase of TSH
level,whichreturnedtothebaseline(pre-
metformin) level within 3 months.
Long-term study
Clinical characteristics and most relevant
datainthethreegroupsofpatientsaresum-
marizedinTable1.Asigniﬁcantdecreaseof
TSH levels after 1 year of metformin treat-
ment was observed in group I and group II
subjects but not in group III subjects. In
detail, mean TSH level was signiﬁcantly re-
duced after 1 year on metformin in group I,
from 2.37  1.17 mIU/l at baseline to
1.41 1.21 (P0.001). Furthermore, six
patientsinthisgroup(20.7%)showedase-
rum TSH level lower than normal 1 year
after starting metformin.
Mean basal TSH level in patients of
group II was 4.5  0.37 mIU/l and signif-
icantly decreased to 2.93  1.48 after 1
year of metformin (P  0.001); TSH re-
duction never reached subnormal levels
in individual patients of this group. Se-
rum FT4 levels did not signiﬁcantly
change during metformin treatments in
any group (Table 1).
CONCLUSIONS — The results of this
study showed that 1) the initiation of treat-
ment with metformin was associated with a
signiﬁcant reduction in the serum levels of
TSH in diabetic patients with primary hy-
pothyroidism both with L-T4 replacement
therapy and untreated; 2) TSH reduction
was not associated with reciprocal changes
in any other thyroid function parameter; 3)
the TSH-lowering effect of metformin de-
veloped slowly and was detectable after a
fewmonthsoftreatment;and4)metformin
had no effect on circulating thyroid func-
tion parameters in euthyroid diabetic
patients.
These data indicate that the thyroidal
repercussion of metformin administration
in diabetic patients may be dual: Although
noeffectisdetectableinpatientswithanor-
mal pituitary-thyroidaxis, signiﬁcant
changesdooccurinpatientswithanunder-
lining thyroid deﬁciency, both with L-T4
therapy and untreated. This is a clinically
relevant observation, especially when con-
sideringthathypothyroidismoccursin10–
15% of type 2 diabetic patients (8) and
many of them are presumably also treated
with metformin.
The mechanism(s) by which met-
forminlowersTSHlevelisstillunclear,and
the design of the present study does not al-
low drawing causal inferences. However,
the present data would exclude biological
interferencesofmetforminwiththeTSHas-
say, increased L-T4 absorption from the
gastrointestinal tract, or any inﬂuence of
changes in body weight associated with
metformin treatment. We hypothesize that
metformin may enhance the inhibitory
modulationofthyroidhormonesoncentral
TSH secretion. Such an effect would not
modify circulating FT3 or TSH levels when
the closed-loop control system is normally
functioning, but may well explain the re-
duction of circulating TSH levels observed
in subjects with altered thyroid-hypophy-
sealfeedback.Anotherexplanatoryhypoth-
esiscouldbethatmetforminamelioratesthe
thyroid function reserve in those patients
with hypothyroidism both treated and un-
treated. Future studies will be needed to
fully elucidate the mechanisms of the here-
described TSH-lowering effect of
metformin.
In conclusion, the results of this study
show that metformin administration in di-
abetic patients with hypothyroidism, both
with L-T4 therapy and untreated, is associ-
ated with a signiﬁcant reduction in the se-
rum levels of TSH, with no change in FT4.
No effect is detectable in patients with an
intact pituitary-thyroid axis. A major clini-
callyrelevantconsequenceofourﬁndingsis
that a reevaluation of thyroid function
within 6–12 months after starting met-
formin seems necessary in diabetic patients
with concomitant hypothyroidism.
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Table 1—Demographic, drug treatment, and thyroid function data in the three groups of
diabetic subjects
Group I Group II Group III
BMI (kg/m
2)
Baseline 32.8  5.6 31.2  4.9 33.0  4.9
After 12 months on metformin 32.1  5.7 30.7  4.9 32.7  4.7
TSH (mIU/l)
Baseline 2.37  1.17 4.52  0.37* 2.74  0.82
After 12 months on metformin 1.41  1.21† 2.93  0.48† 2.56  1.16
FT4 (pg/ml)
Baseline 12.49  2.09 12.51  2.05 12.82  1.90
After 12 months on metformin 12.63  2.72 12.25  1.82 13.09  2.23
Noncategorical data are means  SD. Between-group differences: *P  0.001 for group I vs. group III.
Within-group differences: †P  0.001 for on treatment vs. baseline.
TSH-lowering effect of metformin
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